glen_campbell_bmj

BMJ appoints US managing director

pharmafile | August 9, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMJ, Campbell 

Medical journal BMJ has hired Glen Campbell from Elsevier to be its US managing director.

Campbell joins BMJ on 2 September from Elsevier where he was an executive vice president for Society Business Development, STM Journals. He has spent most of his working life at the firm, where up until his most recent role, he worked in its Health Sciences Division.

More recently, in his role as EVP for Global Medical Research, Campbell was responsible for the worldwide journals programme of Elsevier Health Sciences, overseeing  more than 400 titles.

Advertisement

BMJ chief executive Tim Brooks said: “Glen is a most experienced professional, who brings a lifelong knowledge of medical publishing, and unrivalled contacts in the US health sector. His appointment follows that of Anand Ekambaram to the corresponding role in India, announced last month.”

Campbell added: “I am thrilled to be joining BMJ to work on the expansion of its US business. With the medical research journal in a period of evolution, The BMJ itself has been a dynamic and creative innovator in both content and business models.

“BMJ Clinical Evidence and BMJ Best Practice have also broken new ground in providing clinicians with evidence-based information and knowledge. There is boundless opportunity in the US, and I look forward to building on BMJ’s current success in this market to realise its full potential.”

Related Content

researchers_credit_neusentis_pfizer

Almost half of all cancer drug trials show bias and exaggeration

New research on clinical trials between 2014 and 2016 raise “serious concerns about low standards” …

Xarelto

Investigation questions Xarelto trial data accuracy

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been …

clinical trials

Governments and industry ‘combining to stall drug development’

Both government and industry practices are responsible for the innovation deficit in the pharmaceutical sector, …

The Gateway to Local Adoption Series

Latest content